Lupin launches Luforbec to treat asthma & COPD in UK
It is the first branded generic alternative to Fostair 100/6 pMDI
It is the first branded generic alternative to Fostair 100/6 pMDI
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The data highlights its RSV vaccine cuts hospitalizations in older adults
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Subscribe To Our Newsletter & Stay Updated